Bloomberg Law | April 22, 2023
“This has got to be worrying for the FDA because it means that you’ve got some very powerful justices who are willing to take on FDA’s scientific judgments, not just with this drug, but for others,” said Lawrence Gostin, director of the O’Neill Institute for National and Global Health Law at Georgetown University.